June 2014.- The story of the Catalan firm Grifols is inexorably linked to an ambitious world business view. This 70-year-old healthcare company, with its headquarters in Barcelona, today is present in more than 100 countries and makes products used to treat rare, chronic diseases such as neurological disorders, immune deficiencies, hemophilia and genetic emphysema. Its global view has just taken a further step forward with the inauguration of a new state-of-the-art plasma North Fractionation Facility (NFF) in Clayton, North Carolina in the United States. The plant doubles the production capacity of plasma to approximately 6 million litres annually.
The President of the Catalan Government Artur Mas, taking advantage of an official visit in the US, attended the opening where he declared that Grifols and Catalonia share the same resourceful attitude and open-minded approach. These are the same qualities that have paved the way not only for Grifols, but for many other Catalan firms internationally, such as Desigual, Mango in fashion or Privalia in the ecommerce sphere.
Grifols’ €260 M investment in NFF at its North Carolina facility is part of the company’s Capital Investment Plan for the period 2012-2014. Furthermore, organic growth continues and new investments are planned to expand and increase Grifols' production facilities in both Catalonia and in the United States.
In fact, Grifols plans to allocate approximately €440 M to capital expenditures between 2014 and 2016 for North American investments, as well as further investments in its Parets del Vallès plant in Catalonia.
These investments, both abroad and in Catalonia, strengthen the company’s global presence while reinforcing its position as one of Catalonia’s most dynamic businesses.
Another relevant aspect of this new investment is how it makes it internationally clear how Catalan businesses fully embrace technology in all its forms. This pioneering new plant is the largest of its kind in the world and one of the most innovative. It was recently named the 2014 Facility of the Year for Project Execution by the International Society for Pharmaceutical Engineering (ISPE). The 47,244 square metre facility features technologically advanced systems and processes to ensure the highest standards of product quality and high production capacity in plasma fractionation.